Image of the lithium element and metal.
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Chariot Corporation (ASX:CC9) made a brief announcement to the ASX on Friday, outlining an expansion of landholding.

The company has now expanded its Black Mountain project with another 218 contiguous claims.

All in all, this reflects an expansion of some 206%.

The explorer has also increased its ownership interests in its “Wyoming Lithium Portfolio” to a neat 93.9%, achieved through a share subscription to reimburse Chariot for exploration expenses.

That brings the company’s total hard rock lithium project count to 7 individual plays in the state of Wyoming.

“Each of the projects comprising Chariot’s Wyoming Lithium Portfolio is located in an area without any known land-use encumbrances,” the company wrote on Friday.

Shrugging off macro headwinds in the sector, Chariot is rolling on.

Its Black Mountain play now includes 352 claims officially recognised by the US Federal Bureau of Lands Management (BLM).

“In 2020, Wyoming was ranked 2nd on Fraser Institute’s policy perception index, demonstrating strong government policy support for ongoing mining exploration and development,” Chariot added on Friday.

CC9 shares last traded at 27c.

CC9 by the numbers
More From The Market Online
HotCopper Daily Market Trends Graphic

Monday’s HotCopper Trends: Spartan and Ramelius merger, Arizona capital raise | March 17, 2025

The ASX has been up 0.62% at 7,837 points, following Wall Street’s Friday lead.
Conveyor belt

Image Res eyes 10cps as first heavy concentrate shipped to port

Image Resources jumped 4% in Monday trades after shipping its first heavy mineral concentrate to Geraldton…
Machu Pichu in Peru

Altair confirms 4th porphyry at Venatica West, with high-grade Cu over 700m

Altair Minerals Ltd has identified a fourth porphyry system at its Venatica West project in Peru,…
Cancer concept

Radiopharm has seen breast cancer tumour reductions in first-phase trials

Radiopharm reports its drug 177Lu-RAD202 with a similar imaging agent has seen some patients with breast…